Literature DB >> 23394721

Impaired antioxidant action of high density lipoprotein in patients with type 1 diabetes with normoalbuminuria and microalbuminuria.

Emerson Sampaio1, Décio Sabbatini Barbosa, Tânia Longo Mazzuco, Valéria Sutti Nunes, Marisa Passarelli, Edna Regina Nakandakare, Alexandre José Faria Carrilho.   

Abstract

AIMS: Patients with type 1 diabetes, in the absence of chronic complications, have serum concentrations of high density lipoprotein cholesterol (HDL-C) similar to the general population. However, their HDL particles may be dysfunctional. We aimed to evaluate the antioxidant effect of HDL2 and HDL3 obtained from Caucasian males with type 1 diabetes with normoalbuminuria and microalbuminuria.
METHODS: Twenty Caucasian men with type 1 diabetes (10 with normoalbuminuria and 10 with microalbuminuria) and 10 healthy Caucasian men participated in the study. Lipoproteins were obtained by density gradient ultracentrifugation. The antioxidant effect of HDL was assessed by measuring lipid hydroperoxide (LOOH) concentration after 3h of pooled LDL oxidation catalyzed by 5μM CuSO4 in the absence or presence of HDL2 or HDL3.
RESULTS: The control, normoalbuminuria, and microalbuminuria groups had similar HDL-C concentration and estimated glomerular filtration rate. Glycemic control was similar between diabetes groups (HbA1c 8.1±0.9% and 8.3±0.7%, P=0.70), but estimated glucose disposal rate was lower in patients with microalbuminuria (8.0±0.6 and 4.5±1.1mg/kg/min, P<0.01). The relative antioxidant effect of HDL2 from control, normoalbuminuria, and microalbuminuria groups were 92.8±2.4%, 85.4±1.7%, and 74.2±4.6%, respectively (P<0.01), and the HDL3 effect were 95.0±2.2%, 86.4±4.4%, and 75.3±4.2%, respectively (P<0.01).
CONCLUSION: Both HDL2 and HDL3 inhibited LOOH formation in copper-catalyzed oxidation of LDL in vitro. Overall, this antioxidant effect was lower in Caucasian men with type 1 diabetes, and was further compounded in those with microalbuminuria.
Copyright © 2013. Published by Elsevier Ireland Ltd.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23394721     DOI: 10.1016/j.diabres.2012.12.012

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  6 in total

Review 1.  Dysfunctional HDL in diabetes mellitus and its role in the pathogenesis of cardiovascular disease.

Authors:  Rai Ajit K Srivastava
Journal:  Mol Cell Biochem       Date:  2017-08-21       Impact factor: 3.396

2.  Deoxysphingolipids Upregulate MMP-1, Downregulate TIMP-1, and Induce Cytotoxicity in Human Schwann Cells.

Authors:  Richard L Klein; Andrea Semler; Samar Hammad; Maria F Lopes-Virella; Yan Huang
Journal:  Neuromolecular Med       Date:  2021-12-01       Impact factor: 4.103

3.  Trace elements as predictors of preeclampsia in type 1 diabetic pregnancy.

Authors:  Arpita Basu; Jeremy Y Yu; Alicia J Jenkins; Alison J Nankervis; Kristian F Hanssen; Tore Henriksen; Bjørg Lorentzen; Satish K Garg; M Kathryn Menard; Samar M Hammad; James A Scardo; Christopher E Aston; Timothy J Lyons
Journal:  Nutr Res       Date:  2015-04-11       Impact factor: 3.315

Review 4.  The Role of High-Density Lipoproteins in Diabetes and Its Vascular Complications.

Authors:  Nathan K P Wong; Stephen J Nicholls; Joanne T M Tan; Christina A Bursill
Journal:  Int J Mol Sci       Date:  2018-06-05       Impact factor: 5.923

5.  Lack of Neuroprotective Effects of High-Density Lipoprotein Therapy in Stroke under Acute Hyperglycemic Conditions.

Authors:  David Couret; Cynthia Planesse; Jessica Patche; Nicolas Diotel; Brice Nativel; Steeve Bourane; Olivier Meilhac
Journal:  Molecules       Date:  2021-10-21       Impact factor: 4.411

6.  Administration of CORM-2 inhibits diabetic neuropathy but does not reduce dyslipidemia in diabetic mice.

Authors:  Karen Alejandra Méndez-Lara; David Santos; Núria Farré; Sheila Ruiz-Nogales; Sergi Leánez; José Luis Sánchez-Quesada; Edgar Zapico; Enrique Lerma; Joan Carles Escolà-Gil; Francisco Blanco-Vaca; Jesús María Martín-Campos; Josep Julve; Olga Pol
Journal:  PLoS One       Date:  2018-10-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.